



APPOINTMENT OF A NEW BOARD DIRECTOR

Lure (France), 28 May 2013 – The Combined General Meeting of Vétoquinol Shareholders, which met on 22 May 2013, approved the appointment of Marie-Josèphe Baud as a new Board Director for a period of four years. This appointment raises the percentage of independent directors on the Board from 25% to 33%.

Marie-Josèphe Baud is the head of a management consultancy and pharmaceutical strategy company. Mrs Baud is a graduate of HEC and INSEAD. She began her career at Novartis (1971 to 1997), where she held several positions in market research, strategic planning and business development, prior to becoming Marketing Director, Marketing and Sales Director and Chief Executive Officer of the family healthcare unit. She joined the Pharmacia Group (1997 to 2003) as Head of the Consumer Healthcare Division, and was then appointed Head of European Strategy. Between 2003 and 2007, Mrs Baud was Vice President for Sales & Marketing at TEVA Europe (the leading global generic drugs laboratory), and was appointed Chairwoman of the TEVA France Group in 2006. She was Chairwoman of Sandoz France (Novartis Group) between 2007 and 2010.

Etienne Frechin, Chairman of the Board of Directors, is delighted with the appointment of Marie-Josèphe Baud, *“whose experience strengthens the Vétoquinol Group’s corporate governance, and will help the Group pursue its development”*.

Next update: H1 2013 sales, July 16, 2013 (after market close)

About Vétoquinol

Vétoquinol is a leading global operator in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

An independent pure player, Vétoquinol designs, develops and markets veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol has over 1,800 employees.

Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Investor Relations

Marie-Josée AUBRY-ROTA

Tel.: 03 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor Relations

Emmanuel DOVERGNE

Tel.: 01 56 43 44 63

emmanuel.dovergne@keima.fr

Media Relations

Alix HÉRIARD DUBREUIL

Tel.: 01 56 43 44 62

alix.heriard@keima.fr